EXPRES2ION
LIVE

Serial Number

79159531

Owner

Expres2ion Biotechnologies ApS

Attorney

George S. Pavlik

Filing Date

Mar 14, 2014

Add to watchlist:

No watchlists yet
View on USPTO

EXPRES2ION Trademark

Serial Number: 79159531 • Registration: 4893901

EXPRES2ION is a trademark filed by Expres2ion Biotechnologies ApS on March 14, 2014. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Expres2ion Biotechnologies ApS

Agern Alle 1
Hørsholm DK-2970 , DK

Entity Type: 99

Trademark Details

Filing Date

March 14, 2014

Registration Date

February 2, 2016

Published for Opposition

November 17, 2015

Cancellation Date

March 14, 2024

Goods & Services

[ Chemicals and polymers for medical or veterinary use for use in separation, binding and purification of biological and chemical materials; chemicals, namely, solid phases for medical or veterinary use for use in separation, binding and purification of biological and chemical materials; ] insect cells, insect cell culture media and cell culture reagents all for medical use [ ; pharmaceutical preparations and substances and therapeutic pharmaceuticals for use in the diagnosis, prophylaxis and treatment of cancers, infectious diseases, autoimmune diseases, ophthalmological diseases, metabolic diseases, respiratory diseases, cardiovascular diseases, genetic diseases, and central nervous system conditions; preparations and compositions for therapeutic use, namely, for activating cells of the immune systems; pharmaceutical preparations for use in the treatment of cancer, infectious diseases and immunodeficiencies; antibody-conjugated beads, antibody-conjugated micro-beads and antibody-conjugated microspheres for promoting a therapeutic effect on the body; biological and biochemical preparations for medical purposes for use in the diagnosis, prophylaxis and treatment of cancers, infectious diseases, autoimmune diseases, ophthalmological diseases, metabolic diseases, respiratory diseases, cardiovascular diseases, genetic diseases, and central nervous system conditions; microbiological and tissue culture media, animal blood and serum, and reagents and kits consisting of chemicals, biochemicals, and reagents, all for medical use; chemicals used for medical purposes, namely, reagents, proteins, cells, reagents containing proteins, ligands, effector molecules, and antibodies for medical use ]

Biological reagents for scientific and research purposes; biological and chemical preparations for use in biotechnology, namely, [ oligonucleotides, DNA primers, synthetic oligonucleotides, assays, and ] reagents for use in genetic and proteomics research; [ chemicals and polymers other than for medical or veterinary use for use in separation, binding and purification of biological and chemical materials; chemicals, namely, solid phases other than for medical or veterinary use for use in separation, binding and purification of biological and chemical materials; ] reagents containing ligands, effector molecules and antibodies for scientific and medical research use; [ antibody-conjugated micro-beads and antibody-conjugated microspheres all for scientific and medical research use and for activation of immune system cells; ] chemicals, biochemicals and reagents for use in industry, science and research; [ chemical compositions for scientific and industrial use in the preparation of culture media; media for cell/tissue cultures, cell/tissue culture growth supplements, reagents and buffers for use in cell/tissue cultures, transfection reagents, cryopreservation reagents other than for medical or veterinary purposes; ] reagents containing proteins, ligands, effector molecules and antibodies for scientific or medical research use; biological and biochemical preparations for scientific or medical research use, namely, [ oligonucleotides, DNA primers, synthetic oligonucleotides, assays, and ] reagents for use in genetic and proteomics research; reagents and kits consisting of chemicals, biochemicals and reagents, all for scientific or research use; kits for scientific and research use consisting primarily of [ one or more of the following: proteins, nucleic acids, hormones, purification supports, resins, cells, gels, buffers, stains and associated ] reagents for the expression, amplification, purification and analysis of biological samples; protein and kits consisting primarily of [ oligonucleotides, peptide substrates, assays and ] reagents for use in genetic and proteomics research and for research purposes in biochemical laboratories; [ cell lines for use in scientific, laboratory, diagnostic and medical research; ] biological and chemical preparations for use in biotechnology, namely, [ oligonucleotides, DNA primers, synthetic oligonucleotides, assays, and ] reagents for use in genetic and proteomics research; chemical and biological products for use in medical science, namely, [ oligonucleotides, DNA primers, synthetic oligonucleotides, assays, and ] reagents for use in genetic and proteomics research; [ microbiological and tissue culture media, animal blood and serum, and reagents and kits consisting of chemicals, biochemicals, and reagents, all for scientific research; chemicals used for medical research purposes, namely, reagents containing proteins, ligands, effector molecules, and antibodies for medical research use; ] insect cells, insect cell culture media, and cell culture reagents all for medical laboratory use [ ; reagents and kits consisting of chemicals, biochemicals, and reagents, all for medical diagnostic laboratory use ]

[ Medical and scientific research; research and consultation services in the fields of pharmaceuticals, vaccines, medicine, biological sciences, immunotherapy, and medical devices; development of new products in the fields of pharmaceuticals, medicine, biological sciences, immunotherapy, and medical devices for others; scientific medical laboratory services; research and development for vaccines and new immunotherapy products for others; scientific and technological services, namely, research and design in the fields of medical diagnostics, vaccines, and pharmaceuticals; industrial analysis and research services in the fields of medical diagnostics, vaccines, and pharmaceuticals; research and development services all relating to science; research and development services all relating to industry in the fields of medical diagnostics, vaccines, and pharmaceuticals; research and development services all relating to science; research and development services all relating to biochemistry and biotechnology; research and development services all relating to products and tools to be used in biotechnical research or in biochemical research; ] laboratory research services in the field of gene cloning, gene expression, electrophoresis, protein purification and analysis, and protein interaction detection [ ; providing research data and other molecular biology information for molecular biology reagents and kits in the fields of science and research; scientific research and development; medical and scientific research in the field of molecular biology; biological research; biological cloning services; providing information on the subject of scientific research in the fields of biochemistry and biotechnology; scientific research in the fields of genetics and genetic engineering; biochemical research and development; chemical, biochemical, biological and bacteriological research and analysis; providing reagent sample testing and diagnostic services for others in the field of science and research related thereto; DNA screening for scientific purposes; genetic mapping for scientific purposes; genetic testing for scientific research purposes; providing scientific information via a web site that gives computer users the ability to upload and share video-based scientific protocols and other scientific-based videos; providing information in the field of molecular biology for scientific research purposes, also via on line searchable databases; providing scientific data in protein purification and analysis, and protein interaction detection; medical and scientific research for the development and commercialization of cell-based therapeutic immune system stimulators and enhancers with prophylactic and/or therapeutic purposes; technical research and consultation services in the fields of pharmaceuticals, medicine, biological sciences, immunotherapy, and medical devices; research and development for new immunotherapy products for others; biopharmaceutical research and development; scientific medical laboratory testing and diagnostic services for scientific research purposes; scientific research, namely, developing customized insect culture media, media formulations, and cell culture reagents, and evaluating culture media for others; contract scientific laboratory services and related consulting focused primarily on protein expressions, cell line development, and biotechnology upstream production process development ]

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Oct 8, 2024 DENA
DEATH OF INTERNATIONAL REGISTRATION
Oct 8, 2024 DETH
DEATH OF INTERNATIONAL REGISTRATION
Oct 7, 2024 DETH
DEATH OF INTERNATIONAL REGISTRATION
Oct 7, 2024 DETH
DEATH OF INTERNATIONAL REGISTRATION
Oct 7, 2024 DETH
DEATH OF INTERNATIONAL REGISTRATION
Oct 7, 2024 DETH
DEATH OF INTERNATIONAL REGISTRATION
Oct 7, 2024 DETH
DEATH OF INTERNATIONAL REGISTRATION
Oct 7, 2024 DETH
DEATH OF INTERNATIONAL REGISTRATION
Oct 7, 2024 DETH
DEATH OF INTERNATIONAL REGISTRATION
Oct 7, 2024 DETH
DEATH OF INTERNATIONAL REGISTRATION
Oct 7, 2024 DETH
DEATH OF INTERNATIONAL REGISTRATION
Oct 7, 2024 DETH
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 17, 2023 TCCA
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Mar 17, 2023 EWOR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Mar 17, 2023 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 17, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 17, 2023 REAP
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Aug 30, 2022 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Aug 30, 2022 C75A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Aug 16, 2022 APRE
TEAS SECTION 71 & 15 RECEIVED
Mar 15, 2022 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Feb 2, 2021 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Apr 16, 2020 NREP
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 10, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 10, 2018 REAP
NEW REPRESENTATIVE AT IB RECEIVED
Sep 15, 2016 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 8, 2016 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 4, 2016 FICS
FINAL DISPOSITION PROCESSED
May 4, 2016 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 2, 2016 FICR
REGISTERED-PRINCIPAL REGISTER
Feb 2, 2016 R.PR
NOTIFICATION PROCESSED BY IB
Nov 20, 2015 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 17, 2015 NPUB
PUBLISHED FOR OPPOSITION
Nov 17, 2015 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 4, 2015 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 4, 2015 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 28, 2015 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 14, 2015 PREV
ASSIGNED TO LIE
Oct 8, 2015 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 10, 2015 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 8, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 8, 2015 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Sep 8, 2015 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 7, 2015 GNFN
FINAL REFUSAL E-MAILED
Jul 7, 2015 GNFR
FINAL REFUSAL WRITTEN
Jul 7, 2015 CNFR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 12, 2015 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 12, 2015 REAP
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 12, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 12, 2015 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 12, 2015 TROA
REFUSAL PROCESSED BY IB
Mar 13, 2015 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 24, 2015 RFCS
REFUSAL PROCESSED BY MPU
Feb 24, 2015 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 24, 2015 RFCR
NON-FINAL ACTION WRITTEN
Feb 23, 2015 CNRT
NON-FINAL ACTION WRITTEN
Feb 23, 2015 CNRT
APPLICATION FILING RECEIPT MAILED
Feb 10, 2015 MAFR
ASSIGNED TO EXAMINER
Feb 6, 2015 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 6, 2015 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 5, 2015 REPR